| Date | Title | Description | Source |
| 14.03.2024 | Pi Health Secures $30M to Democratize Cancer Clinical Trials | Pi Health Co-Founders Bobby Reddy, MD, COO & Geoff Kim, CEO (left to right)
What You Should Know... | hitconsult... |
| 10.03.2024 | Blockbuster BeiGene Cancer Drug Adds Another FDA Approval | A BeiGene drug already used to treat several types of blood cancer now has an additional FDA approva... | medcitynew... |
| 12.07.2023 | Putting Patients First: The Quest to Make Anticancer Cell Th... | TAIPEI, July 12, 2023 /PRNewswire/ -- As cell therapies continue to rank among the most expensive of... | en.prnasia... |
| 03.02.2023 | New Talk About It Resources Aim to Accelerate Integration of... | BeiGene Releases Report and Launches CancerandMentalHealth.com in Conjunction with World Cancer Day ... | aithority.... |
| 27.06.2022 | Antengene Announces Clinical Trial Collaboration with BeiGen... | - Selinexor is an oral small molecule XPO1 inhibitor; tislelizumab is an anti-PD-1 checkpoint inhibi... | en.prnasia... |
| 18.12.2021 | BeiGene : Announces Closing of Its RMB22.2 Billion (US$3.5 B... | BeiGene Announces Closing of Its RMB22.2 Billion (US$3.5 Billion) Initial Public Offering on the STA... | marketscre... |
| 15.12.2021 | BeiGene Announces Closing of Its RMB22.2 Billion (US$3.5 Bil... | BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global, science-driven biotechnology compa... | marketscre... |
| 07.12.2021 | BeiGene : Announces Pricing of its RMB22.2 billion (US$3.5 b... | BeiGene Announces Pricing of its RMB22.2 billion (US$3.5 billion) Initial Public Offering on the STA... | marketscre... |
| 30.11.2021 | BeiGene Announces Pricing of its RMB22.2 billion (US$3.5 bil... | BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a global, science-driven biotechnology company focused on... | marketscre... |
| 02.09.2021 | FDA approves BeiGene's Brukinsa in rare blood cancer amid... | BeiGene has been anything but shy about its US expansion plans centered around blood cancer dru... | endpts.com... |
| 31.08.2021 | In a major blow to vaccine efforts, senior FDA leaders ... | A group of powerhouse biotech leaders is coming together to launch a new nonprofit, one aimed at del... | endpts.com... |
| 02.08.2021 | Drug supplier Abcam brings a longtime collaborator i... | BeiGene blazed the trail for a growing wave of Chinese oncology drugs breaking through in the US wit... | endpts.com... |
| 17.06.2021 | BEIGENE, LTD.
BeiGene : Announces First Patient Dosed in Gl... | BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a global biotechnology company focused on developing and ... | marketscre... |
| 03.06.2021 | ZHONGCHAO INC.
Zhongchao Inc. : Announces the On-Going One-... | SHANGHAI, June 3, 2021 /PRNewswire/ -- Zhongchao Inc. (NASDAQ: ZCMD) ("Zhongchao" or the &... | marketscre... |
| 02.03.2021 | Health Canada Approves BRUKINSA® (Zanubrutinib) for the Trea... | CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)--Mar 2, 2021--
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06... | oaoa.com/n... |
| 26.02.2021 | BeiGene Announces Closing of Collaboration with Novartis to ... | CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)--Feb 26, 2021--
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 0... | oaoa.com/n... |
| 01.12.2020 | Chinese edtech startup EEO Education gains US$ 265M in Serie... | EEO Education was founded in 2014 and launched its first online classroom software, ClassIn, in 2015... | vcbay.news... |
| 22.10.2020 | Biden And Trump Drug Pricing Policies Would Decimate Biotech... | President Donald Trump signs an executive order linking drug prices to rates paid in other ... [+] c... | forbes.com... |
| 01.09.2020 | STAT China: Lineup for Hong Kong IPO grows, and a conversati... | A version of this digest first appeared in the weekly STAT China newsletter. To receive future editi... | statnews.c... |
| 29.05.2020 | As tislelizumab gains traction in China, BeiGene pulls th... | In a world now brimming with checkpoint inhibitors, companies often struggle to make a mark g... | endpts.com... |
| 14.05.2020 | Private Sector Tracker: How Asia’s Companies Are Responding ... | SeegeneSHIN IN-SEOP/FORBES KOREA | forbes.com... |
| 14.04.2020 | BeiGene reports positive Phase III interim analysis for lung... | The company said it plans to file for approval of the drug with Chinese drug regulators and present ... | medcitynew... |
| 01.04.2020 | Coronavirus Business Tracker: How The Private Sector Is Figh... | Alain Mérieux, founder of BioMérieux.AFP via Getty Images | forbes.com... |
| 16.12.2019 | BeiGene’s Phase III Waldenström’s study misses mark, but wit... | Shares of BeiGene were down more than 7% on the Nasdaq Monday afternoon.
ASPEN’s primary endpoint wa... | medcitynew... |
| 22.11.2019 | Zymeworks & BeiGene Advance ZW25 into Potentially Regist... | SINGAPORE — Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multi... | lumiravent... |
| 05.11.2019 | Steve Kafka joins Section 32 as managing partner; Take... | Steven Kafka
→ Former Thrive CEO and partner at Third Rock Ventures, Steve Kafka, has hopped ab... | endpts.com... |
| 01.11.2019 | Amgen takes out big stake in BeiGene for $2.7B in strategic ... | Shares of BeiGene were up 30 percent on the Nasdaq Friday morning following the announcement. Shares... | medcitynew... |
| 13.02.2019 | For a Chinese cancer drug developer, Bristol-Celgene deal is... | SAN FRANCISCO — Celgene is famous for cultivating a constellation of biotech partners — companies wh... | statnews.c... |
| 15.01.2019 | China’s BeiGene gets FDA breakthrough therapy designation fo... | In MCL, the company has a Phase II clinical trial of 86 patients enrolled at 17 sites in China. BeiG... | medcitynew... |
| 08.08.2018 | BeiGene takes a hit after historic $903M Hong Kong IPO wit... | The first day of its secondary listing in Hong Kong has proven slightly disappointing for BeiG... | endpts.com... |
| 02.08.2018 | BeiGene bags a staggering $903M IPO on the HKEX — and stil... | BeiGene’s secondary IPO on the Hong Kong exchange says a lot about the sky-high expectations of... | endpts.com... |
| 27.07.2018 | In for the China biotech gold rush, BeiGene eyes monster $... | Fast on the heels of Ascletis’ record $400 million raise on the Hong Kong stock exchange, BeiGen... | endpts.com... |
| 06.07.2017 | Term Sheet — Thursday, July 6 | THREE UNRELATED THINGS
FALSE START: The finance world experienced a big letdown yesterday, after rep... | fortune.co... |
| 29.06.2016 | The biotech IPO feast flags as investors lose their appeti... | There was a time after the 2008 crash that biotech IPOs were about as popular as snow in March. B... | endpts.com... |
| 16.10.2015 | Chinese cancer immunotherapy player BeiGene files for $100M ... | Advancing its clinical stage pipeline. BeiGene has an open IND with the U.S. FDA for its BTK inhibit... | medcitynew... |
| 15.05.2015 | Funding roundup - week ending 5/15/15 | DocPlanner, DocuSign, Grab, Silversheet, Knod, Actiance, NerdWallet, Wave, MarkLogic, Instart Logic
... | vator.tv/n... |
| 13.05.2015 | BeiGene Completes $US97M Financing | BeiGene Ltd., a Cayman Islands exempted oncology company focused on developing targeted and immuno-o... | finsmes.co... |
| 13.05.2015 | China's BeiGene banks $97M to get its cancer drugs into the ... | BeiGene CEO John Oyler has long said China has all the world-class science and entrepreneurial ambit... | fiercebiot... |
| 14.11.2014 | BeiGene Receives $75M in Funding | BeiGene, a Beijing, China-based oncology company, received $75m in funding.
Backers included initial... | finsmes.co... |
| - | BeiGene reports positive Phase III interim analysis for lung... | Interim results from a Phase III clinical trial have shown that patients receiving a cancer immunoth... | medcitynew... |
| - | BeiGene Tumbles on Shanghai Star Market Debut, But Still Rai... | (Yicai Global) Dec. 15 -- Shares in BeiGene plunged 16.4 percent on their first day of trading on th... | yicaigloba... |
| - | Chinese cancer immunotherapy player BeiGene files for $100M ... | China-based cancer immunotherapy company BeiGene just filed with the SEC for a $100 million IPO, reg... | medcitynew... |
| - | BeiGene Initiates Phase 1 Clinical Trial for HPK1 Inhibitor ... | CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)--Mar 10, 2021--
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 0... | oaoa.com/n... |
| - | BeiGene Announces Presentation of Clinical and Preclinical D... | CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)--Mar 10, 2021--
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 0... | oaoa.com/n... |
| - | Amgen takes out big stake in BeiGene for $2.7B in strategic ... | Biotech company Amgen will acquire more than one-fifth of an up-and-coming Chinese biotech company a... | medcitynew... |
| - | BeiGene Reports Fourth Quarter and Full Year 2020 Financial ... | CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)--Feb 25, 2021--
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 0... | oaoa.com/n... |
| - | BeiGene Announces Acceptance of a Supplemental Biologics Lic... | BEIJING & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar 5, 2021--
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06... | oaoa.com/n... |
| - | BeiGene’s Phase III Waldenström’s study misses mark, but wit... | A Chinese biotech company that just won Food and Drug Administration approval for its lead candidate... | medcitynew... |
| - | Asia-Pacific markets fall ahead of U.S. inflation data | This is CNBC’s live blog covering Asia-Pacific markets. | cnbc.com/2... |
| - | China’s BeiGene gets FDA breakthrough therapy designation fo... | A Chinese firm has received breakthrough therapy designation from the Food and Drug Administration f... | medcitynew... |
